In pre-treatment blood samples from non-M3 AML patients, low baseline levels of IGFBP-1 and IGFBP-6 correlate with better progression-free survival, while low baseline levels of IGFBP-2, IGFBP-2, IGFBP-6, and IGFBP-7 are closely associated with improved overall survival (181). The gene discussed is IGFBP6; the disease is acute myeloid leukemia.